Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014, Article ID 850493, 11 pages
http://dx.doi.org/10.1155/2014/850493
Research Article

An In Vivo Microdialysis Study of FLZ Penetration through the Blood-Brain Barrier in Normal and 6-Hydroxydopamine Induced Parkinson’s Disease Model Rats

State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China

Received 3 April 2014; Revised 18 May 2014; Accepted 21 May 2014; Published 23 June 2014

Academic Editor: Mahendra Pratap Singh

Copyright © 2014 Jinfeng Hou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. E. Gillies, I. S. Pienaar, S. Vohra, and Z. Qamhawi, “Sex differences in Parkinson's disease,” Frontiers in Neuroendocrinology, 2014. View at Publisher · View at Google Scholar
  2. O. M. E. Abdel-Salam, “Drugs used to treat Parkinson's disease, present status and future directions,” CNS and Neurological Disorders: Drug Targets, vol. 7, no. 4, pp. 321–342, 2008. View at Publisher · View at Google Scholar · View at Scopus
  3. K. Strecker and J. Schwarz, “Parkinson's disease: emerging pharmacotherapy,” Expert Opinion on Emerging Drugs, vol. 13, no. 4, pp. 573–591, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Xie, X. Z. Jiao, X. T. Liang, W. H. Feng, H. L. Wei, and G. T. Liu, “Synthesis and antioxiactivity of squamosamide cyclic analogs,” Acta Academiae Medicinae Sinicae, vol. 26, no. 4, pp. 372–378, 2004. View at Google Scholar · View at Scopus
  5. H. Y. Pang, G. Liu, and G. T. Liu, “Compound FLZ inhibits lipopolysaccharide-induced inflammatory effects via down-regulation of the TAK-IKK and TAK-JNK/p38MAPK pathways in RAW264.7 macrophages,” Acta Pharmacologica Sinica, vol. 30, no. 2, pp. 209–218, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. X. Q. Bao, X. C. Kong, C. Qian, and D. Zhang, “FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson's disease models,” Neuroscience, vol. 202, pp. 396–404, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. X. C. Kong, D. Zhang, C. Qian, G. T. Liu, and X. Q. Bao, “FLZ, a novel HSP27 and HSP70 inducer, protects SH-SY5Y cells from apoptosis caused by MPP+,” Brain Research, vol. 1383, pp. 99–107, 2011. View at Publisher · View at Google Scholar · View at Scopus
  8. N. Li and G. T. Liu, “The novel squamosamide derivative FLZ enhances BDNF/TrkB/CREB signaling and inhibits neuronal apoptosis in APP/PS1 mice,” Acta Pharmacologica Sinica, vol. 31, no. 3, pp. 265–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Zhang, X. Hu, S. J. Wei et al., “Squamosamide derivative FLZ protects dopaminergic neurons against inflammation-mediated neurodegeneration through the inhibition of NADPH oxidase activity,” Journal of Neuroinflammation, vol. 5, article 21, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Zhang, J. J. Zhang, and G. T. Liu, “The novel squamosamide derivative (compound FLZ) attenuated 1-methyl, 4-phenyl-pyridinium ion (MPP+)-induced apoptosis and alternations of related signal transduction in SH-SY5Y cells,” Neuropharmacology, vol. 52, no. 2, pp. 423–429, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. D. Zhang, J. J. Zhang, and G. T. Liu, “The novel squamosamide derivative FLZ protects against 6-hydroxydopamine-induced apoptosis through inhibition of related signal transduction in SH-SY5Y cells,” European Journal of Pharmacology, vol. 561, no. 1–3, pp. 1–6, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. F. Fang and G. T. Liu, “Protective effects of compound FLZ on β-amyloid peptide-(25-35)-induced mouse hippocampal injury and learning and memory impairment,” Acta Pharmacologica Sinica, vol. 27, no. 6, pp. 651–658, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. W. Feng, H. Wei, and G. T. Liu, “Pharmacological study of the novel compound FLZ against experimental Parkinson's models and its active mechanism,” Molecular Neurobiology, vol. 31, no. 1–3, pp. 295–300, 2005. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. Hou, Y. B. Yu, G. Liu, and Y. Luo, “A natural squamosamide derivative FLZ reduces amyloid-β production by increasing non-amyloidogenic AβPP processing,” Journal of Alzheimer's Disease, vol. 18, no. 1, pp. 153–165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Fang, Q. L. Wang, and G. T. Liu, “FLZ, synthetic squamosamide cyclic derivative, attenuates memory deficit and pathological changes in mice with experimentally induced aging,” Naunyn-Schmiedeberg's Archives of Pharmacology, vol. 385, no. 6, pp. 579–585, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Fang and G. Liu, “A novel cyclic squamosamide analogue compound FLZ improves memory impairment in artificial senescence mice induced by chronic injection of D-galactose and NaNO2,” Basic and Clinical Pharmacology and Toxicology, vol. 101, no. 6, pp. 447–454, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. J. Hou, F. Qu, C. Wu, Q. Ren, and J. Zhang, “Quantitative determination and pharmacokinetic study of the novel anti-Parkinson's disease candidate drug FLZ in rat brain by high performance liquid chromatography-tandem mass spectrometry,” Journal of Pharmaceutical and Biomedical Analysis, vol. 66, pp. 232–239, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. J. H. Lin, “CSF as a surrogate for assessing CNS exposure: an industrial perspective,” Current Drug Metabolism, vol. 9, no. 1, pp. 46–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. R. J. Sawchuk and W. F. Elmquist, “Microdialysis in the study of drug transporters in the CNS,” Advanced Drug Delivery Reviews, vol. 45, no. 2-3, pp. 295–307, 2000. View at Publisher · View at Google Scholar · View at Scopus
  20. F. E. O'Brien, G. Clarke, P. Fitzgerald, T. G. Dinan, B. T. Griffin, and J. F. Cryan, “Inhibition of P-glycoprotein enhances transport of imipramine across the blood-brain barrier: microdialysis studies in conscious freely moving rats,” British Journal of Pharmacology, vol. 166, no. 4, pp. 1333–1343, 2012. View at Publisher · View at Google Scholar · View at Scopus
  21. E. C. M. de Lange, A. G. de Boer, and D. D. Breimer, “Methodological issues in microdialysis sampling for pharmacokinetic studies,” Advanced Drug Delivery Reviews, vol. 45, no. 2-3, pp. 125–148, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. C. S. Chaurasia, M. Müller, E. D. Bashaw et al., “AAPS-FDA workshop white paper: microdialysis principles, application and regulatory perspectives,” Pharmaceutical Research, vol. 24, no. 5, pp. 1014–1025, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. T. H. Tsai, S. C. Liu, P. L. Tsai, L. K. Ho, A. Y. C. Shum, and C. F. Chen, “The effects of the cyclosporin A, a P-glycoprotein inhibitor, on the pharmacokinetics of baicalein in the rat: a microdialysis study,” British Journal of Pharmacology, vol. 137, no. 8, pp. 1314–1320, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. K. L. Woo and C. E. Lunte, “The development of multiple probe microdialysis sampling in the stomach,” Journal of Pharmaceutical and Biomedical Analysis, vol. 48, no. 1, pp. 20–26, 2008. View at Publisher · View at Google Scholar · View at Scopus
  25. N. J. Abbott, A. A. K. Patabendige, D. E. M. Dolman, S. R. Yusof, and D. J. Begley, “Structure and function of the blood-brain barrier,” Neurobiology of Disease, vol. 37, no. 1, pp. 13–25, 2010. View at Publisher · View at Google Scholar · View at Scopus
  26. B. T. Hawkins and T. P. Davis, “The blood-brain barrier/neurovascular unit in health and disease,” Pharmacological Reviews, vol. 57, no. 2, pp. 173–185, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Y. Kim, M. Buckwalter, H. Soreq, A. Vezzani, and D. Kaufer, “Blood-brain barrier dysfunction-induced inflammatory signaling in brain pathology and epileptogenesis,” Epilepsia, vol. 53, pp. 37–44, 2012. View at Google Scholar · View at Scopus
  28. J. E. Westin, H. S. Lindgren, J. Gardi et al., “Endothelial proliferation and increased blood-brain barrier permeability in the basal ganglia in a rat model of 3,4-dihydroxyphenyl-L-alanine-induced dyskinesia,” Journal of Neuroscience, vol. 26, no. 37, pp. 9448–9461, 2006. View at Publisher · View at Google Scholar · View at Scopus
  29. H. E. de Vries, G. Kooij, D. Frenkel, S. Georgopoulos, A. Monsonego, and D. Janigro, “Inflammatory events at blood-brain barrier in neuroinflammatory and neurodegenerative disorders: implications for clinical disease,” Epilepsia, vol. 53, supplement 6, pp. 45–52, 2012. View at Google Scholar · View at Scopus
  30. V. Pisani, A. Stefani, M. Pierantozzi et al., “Increased blood-cerebrospinal fluid transfer of albumin in advanced Parkinson's disease,” Journal of Neuroinflammation, vol. 9, article 188, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. R. Kortekaas, K. L. Leenders, J. C. H. van Oostrom et al., “Blood-brain barrier dysfunction in Parkinsonian midbrain in vivo,” Annals of Neurology, vol. 57, no. 2, pp. 176–179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  32. M. F. Beal, “Experimental models of Parkinson's disease,” Nature Reviews Neuroscience, vol. 2, no. 5, pp. 325–332, 2001. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Schober, “Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP,” Cell and Tissue Research, vol. 318, no. 1, pp. 215–224, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. Przedborski, V. Jackson-Lewis, A. B. Naini et al., “The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a technical review of its utility and safety,” Journal of Neurochemistry, vol. 76, no. 5, pp. 1265–1274, 2001. View at Publisher · View at Google Scholar · View at Scopus
  35. N. Schmidt and B. Ferger, “Neurochemical findings in the MPTP model of Parkinson's disease,” Journal of Neural Transmission, vol. 108, no. 11, pp. 1263–1282, 2001. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Betarbet, T. B. Sherer, and J. Timothy Greenamyre, “Animal models of Parkinson's disease,” BioEssays, vol. 24, no. 4, pp. 308–318, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. A. L. Bartels, A. T. M. Willemsen, R. Kortekaas et al., “Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP and MSA,” Journal of Neural Transmission, vol. 115, no. 7, pp. 1001–1009, 2008. View at Publisher · View at Google Scholar · View at Scopus
  38. M. Westerlund, A. C. Belin, L. Olson, and D. Galter, “Expression of multi-drug resistance 1 mRNA in human and rodent tissues: reduced levels in Parkinson patients,” Cell and Tissue Research, vol. 334, no. 2, pp. 179–185, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. R. L. Shepard, J. Cao, J. J. Starling, and A. H. Dantzig, “Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979,” International Journal of Cancer, vol. 103, no. 1, pp. 121–125, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. L. J. Green, P. Marder, and C. A. Slapak, “Modulation by LY335979 of P-glycoprotein function in multidrug-resistant cell lines and human natural killer cells,” Biochemical Pharmacology, vol. 61, no. 11, pp. 1393–1399, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. A. H. Dantzig, R. L. Shepard, K. L. Law et al., “Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities,” Journal of Pharmacology and Experimental Therapeutics, vol. 290, no. 2, pp. 854–862, 1999. View at Google Scholar · View at Scopus
  42. J. J. Starling, R. L. Shepard, J. Cao et al., “Pharmacological characterization of LY335979: a potent cyclopropyldibenzosuberane modulator of P-glycoprotein,” Advances in Enzyme Regulation, vol. 37, pp. 335–347, 1997. View at Publisher · View at Google Scholar · View at Scopus
  43. A. H. Dantzig, K. L. Law, J. Cao, and J. J. Starling, “Reversal of multidrug resistance by the P-glycoprotein modulator, LY335979, from the bench to the clinic,” Current Medicinal Chemistry, vol. 8, no. 1, pp. 39–50, 2001. View at Google Scholar · View at Scopus
  44. E. H. Rubin, D. P. de Alwis, I. Pouliquen et al., “A Phase I trial of a potent P-glycoprotein inhibitor, Zosuquidar·3HCl trihydrochloride (LY335979), administered orally in combination with doxorubicin in patients with advanced malignancies,” Clinical Cancer Research, vol. 8, no. 12, pp. 3710–3717, 2002. View at Google Scholar · View at Scopus
  45. P. M. Fracasso, L. J. Goldstein, D. P. de Alwis et al., “Phase I study of docetaxel in combination with the P-glycoprotein inhibitor, zosuquidar, in resistant malignancies,” Clinical Cancer Research, vol. 10, no. 21, pp. 7220–7228, 2004. View at Publisher · View at Google Scholar · View at Scopus
  46. K. S. Shin, H. S. Choi, T. T. Zhao et al., “Neurotoxic effects of berberine on long-term l-DOPA administration in 6-hydroxydopamine-lesioned rat model of Parkinson's disease,” Archives of Pharmacal Research, vol. 36, no. 6, pp. 759–767, 2013. View at Publisher · View at Google Scholar · View at Scopus
  47. G. Paxinos and C. Watson, The Mouse Brain in Stereotaxic Coordinates, vol. 3, People's Medical Publishing House, Beijing, China, 3rd edition, 2005.
  48. E. Thornton and R. Vink, “Treatment with a substance p receptor antagonist is neuroprotective in the intrastriatal 6-hydroxydopamine model of early parkinson's disease,” PLoS ONE, vol. 7, no. 4, Article ID e34138, 2012. View at Publisher · View at Google Scholar · View at Scopus
  49. E. M. Kemper, C. Cleypool, W. Boogerd, J. H. Beijnen, and O. van Tellingen, “The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice,” Cancer Chemotherapy and Pharmacology, vol. 53, no. 2, pp. 173–178, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. B. D. Anderson, M. J. May, S. Jordan, L. Song, M. J. Roberts, and M. Leggas, “Dependence of nelfinavir brain uptake on dose and tissue concentrations of the selective P-glycoprotein inhibitor zosuquidar in rats,” Drug Metabolism and Disposition, vol. 34, no. 4, pp. 653–659, 2006. View at Publisher · View at Google Scholar · View at Scopus
  51. Y. Chen, S. Agarwal, N. M. Shaik, C. Chen, Z. Yang, and W. F. Elmquist, “P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib,” Journal of Pharmacology and Experimental Therapeutics, vol. 330, no. 3, pp. 956–963, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. R. Nirogi, V. Kandikere, G. Bhyrapuneni et al., “Approach to reduce the non-specific binding in microdialysis,” Journal of Neuroscience Methods, vol. 209, no. 2, pp. 379–387, 2012. View at Publisher · View at Google Scholar · View at Scopus
  53. S. Raje, J. Cao, A. H. Newman, H. Gao, and N. D. Eddington, “Evaluation of the blood-brain barrier transport, population pharmacokinetics, and brain distribution of benztropine analogs and cocaine using in vitro and in vivo techniques,” Journal of Pharmacology and Experimental Therapeutics, vol. 307, no. 2, pp. 801–808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Erdo, J. Gordon, J. T. Wu, and I. Sziráki, “Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats,” Brain Research Bulletin, vol. 87, no. 4-5, pp. 413–419, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. P. M. Carvey, C. H. Zhao, B. Hendey et al., “6-Hydroxydopamine-induced alterations in blood-brain barrier permeability,” European Journal of Neuroscience, vol. 22, no. 5, pp. 1158–1168, 2005. View at Publisher · View at Google Scholar · View at Scopus